A plus AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation

被引：0

作者：

Heyman, Benjamin ^{[1
]}

Choi, Michael ^{[2
]}

Kipps, Thomas J. ^{[3
]}

机构：

[1] UC San Diego Moores Canc Ctr, Dept Med, Div Regenerat Med, UC San Diego, La Jolla, CA 92093 USA

[2] Dept Med, Div Hematol Oncol, UC San Diego, La Jolla, CA 92093 USA

[3] Ctr Novel Therapeut, Dept Med, Div Hematol Oncol, UC San Diego, La Jolla, CA 92093 USA

来源：

CASE REPORTS IN HEMATOLOGY | 2024年 / 2024卷

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; PHASE-II; CHEMOTHERAPY; VENETOCLAX; OUTCOMES; THERAPY; DISEASE; ABVD; MOPP;

D O I：

10.1155/2024/7612622

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma variant of Richter's transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.

引用

页数：8

共 50 条

[31] Treatment results in advanced stage Hodgkin's lymphoma: A retrospective study
Jain, H.
Sengar, M.
Nair, R.
Menon, H.
Laskar, S.
Shet, T.
Gujral, S.
Sridhar, E.
JOURNAL OF POSTGRADUATE MEDICINE, 2015, 61 (02) : 88 - 91
[32] Hodgkin’s disease variant of richter’s transformationA case report
Abdurrahman Isikdogan
Orhan Ayyildiz
Hüseyin Büyükbayram
Ekrem Müftüoğlu
Medical Oncology, 2002, 19 : 109 - 112
[33] Smart salvage treatment for Hodgkin lymphoma
Johnson, Peter W. M.
BLOOD, 2022, 139 (25) : 3563 - 3564
[34] Novel agents for the treatment of Hodgkin lymphoma
Dumaswala, Komal
Mehta, Amitkumar
EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (05) : 659 - 667
[35] Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison
Keeping, Sam
Wu, Elise
Chan, Keith
Mojebi, Ali
Ferrante, Shannon Allen
Balakumaran, Arun
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (06) : 503 - 511
[36] Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated with EBV infection
de Leval, L
Vivario, M
De Prijck, B
Zhou, YP
Boniver, J
Harris, NL
Isaacson, P
Du, MQ
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (05) : 679 - 686
[37] Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG)
Jamroziak, Krzysztof
Szymczyk, Agnieszka
Hus, Marek
Wojciechowska, Malgorzata
Knopinska-Posluszny, Wanda
Holojda, Jadwiga
Halaburda, Kazimierz
Warzocha, Krzysztof
Iskierka-Jazdzewska, Elzbieta
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (04) : 389 - 391
[38] New developments in the treatment of advanced Hodgkin's lymphoma
Kreissl, S.
Eichenauer, D.
Borchmann, P.
ONKOLOGE, 2014, 20 (05): : 457 - +
[39] Hodgkin's lymphoma: who needs consolidation treatment?
Engert, Andreas
LANCET, 2015, 385 (9980) : 1810 - 1812
[40] SEOM clinical guidelines for the treatment of Hodgkin's lymphoma
Quero Blanco, Cristina
Garcia Arroyo, Ramon
Provencio Pulla, Mariano
Rueda Dominguez, Antonio
Isla Casado, Dolores
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (11) : 753 - 759

← 1 2 3 4 5 →